

**Faculty List for Tufts CSDD 2017 Annual Postgraduate Course in
Clinical Pharmacology Drug Development, and Regulation****Kenneth I Kaitin, PhD**

Professor & Director, Tufts Center for the Study of Drug Development, Tufts University School of Medicine

Richard I. Shader, MD

Professor Emeritus, Department of Integrative Physiology and Pathobiology, Professor Emeritus, Department of Psychiatry, Tufts University School of Medicine

Paul R. Beninger, MD, MBA

Therapeutic Area Head, Pharmacovigilance (Genzyme), and Assistant Professor, Public Health & Community Medicine, TUSM)

Helen W. Boucher, MD

Director, Infectious Diseases Fellowship Program, Director, Ventricular Assist Device and Heart Transplant Infectious Diseases Program Associate Professor of Medicine, Tufts Medical Center

Jerry M. Collins, PhD

Associate Director, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, NCI, NIH

Michael H. Court, PhD

Professor and Jones Endowed Chair in Individualized Medicine, Washington State University, College of Veterinary Medicine

Janet Forrester, PhD

Associate Professor, Department of Public Health & Community Medicine, Tufts University School of Medicine

Kenneth A. Getz, MBA

Director of Sponsored Research Programs, Tufts Center for the Study of Drug Development, Tufts University

Alberto Grignolo, PhD

Corporate VP, Global Strategy and Services PAREXEL Consulting

Laurie A. Halloran, BSN, MS

President & CEO, Halloran Consulting Group, Inc.

Laura Housman, MPH, MBA

Global Head, Pharmaceutical Business, SVP, Corporate Development, Molecular Health

Judith K. Jones, MD, PhD

President & CEO, The Degge Group, Ltd.

Peter Keeling

CEO, Diaceutics

Robert A. Morgan, MS, JD

VP Regulatory Affairs/Quality, MediVector, Inc.

Chandrasekhar Natarajan, MS, MSc

Chief Scientific Officer, ViNa Pharma Consultants

Peter J. Neumann, ScD

Director, Center for the Evaluation of Value & Risk in Health, Professor of Medicine, Tufts Medical Center

Michele K. Russell-Einhorn, JD

Vice President, Oncology, Schulman Associates IRB

Niranjan Y. Sardesai, PhD

Chief Operating Officer, Inovio Pharmaceuticals

Jerald S. Schindler, DrPH

Vice President, Global Late Development Biostatistics, Merck Research Laboratories

Alison Taunton-Rigby, PhD, OBE

Director & Trustee, Healthcare, Life Sciences and Financial Services

Ellis F. Unger, MD

Director, Office of Drug Evaluation-I, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration

Karthik Venkatakrishnan, PhD

Senior Director, Clinical Pharmacology, Takeda Pharmaceuticals International Company

Tal Zaks, MD, PhD

Chief Medical Officer, Moderna Therapeutics